Drugs / TAK-536CCB
last change Dec 2013 re-read 2 minutes ago

TAK-536CCB

Developed for
essential hypertension

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT02072330 Comparator Mar → Dec 2013 essential hypertension Takeda Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TAK-536CCB ClinicalTrials.gov intervention name — accepted as the source's own label NCT02072330
Known as Fix-dose combination of Azilsartan and Amlodipine Fix-dose combination of Azilsartan and AmlodipineNCT02072330